Evaluation of effectiveness of mass screening for colorectal cancer
- PMID: 2238667
- DOI: 10.1007/BF01658816
Evaluation of effectiveness of mass screening for colorectal cancer
Abstract
As the first step in the epidemiological evaluation of the effectiveness of mass screening for colorectal cancer, we compared clinicopathological features and survival rates of patients with cancer detected by mass screening (screened group) with those for patients treated in our outpatient clinic in the same period (outpatient group). The screened group consisted of 53 patients with colorectal cancer detected by 2-day or 3-day screening for fecal occult blood by guaiac slides. Their background factors were comparable to those of 120 patients of the outpatient group in regard to age, sex ratio, location of cancer, and histological type of cancer. In the screened group, 90% of patients had no complaints, and positive occult blood tests led to the detection of cancers. More than 60% of the patients had Dukes' A and B1 early cancers while only about 30% had advanced cancers. In the outpatient group, nearly 90% of patients were symptomatic, most commonly from rectal bleeding. Early-stage cancers made up only 20%, and large, advanced-stage cancers accounted for 80%. The 5-year survival rate of the screened group was 91.5%, being significantly higher than the 60% survival rate for the outpatient group. It is anticipated that mass screening for colorectal cancer by guaiac fecal occult blood testing will significantly reduce the mortality due to this neoplasm.
Similar articles
-
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.J Natl Cancer Inst. 1999 Mar 3;91(5):434-7. doi: 10.1093/jnci/91.5.434. J Natl Cancer Inst. 1999. PMID: 10070942
-
A comparative study on the efficacy of a mass screening program for colorectal cancer--comparison between cancer cases detected by mass screening and by outpatient clinics.Asia Pac J Public Health. 1994;7(3):159-64. doi: 10.1177/101053959400700303. Asia Pac J Public Health. 1994. PMID: 7794654
-
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.Gastroenterology. 2017 Aug;153(2):439-447.e2. doi: 10.1053/j.gastro.2017.05.004. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483499
-
[Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].Gan To Kagaku Ryoho. 1998 Aug;25(10):1514-8. Gan To Kagaku Ryoho. 1998. PMID: 9725042 Review. Japanese.
-
Screening for colorectal cancer: current status in Japan.Dis Colon Rectum. 2000 Oct;43(10 Suppl):S78-84. doi: 10.1007/BF02237230. Dis Colon Rectum. 2000. PMID: 11052482 Review.
Cited by
-
Occurrence and clinical significance of overt blood loss per rectum in the general population and in medical practice.Br J Gen Pract. 1994 Jul;44(384):320-5. Br J Gen Pract. 1994. PMID: 8068381 Free PMC article. Review.
-
General surgery.Postgrad Med J. 1991 Oct;67(792):876-91. doi: 10.1136/pgmj.67.792.876. Postgrad Med J. 1991. PMID: 1758797 Free PMC article. Review. No abstract available.
-
Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations.BMC Med Genet. 2007 Jul 2;8:42. doi: 10.1186/1471-2350-8-42. BMC Med Genet. 2007. PMID: 17605803 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials